The cell engineering company, co-founded by oncologist and writer Siddhartha Mukherjee, does not see a path forward for its pipeline of early-stage cell therapies for two different types of cancer.
Vor Bio Looks for Exit in Challenging Funding Environment; Lays Off 95% of Staff
